Oncotarget

Research Papers: Immunology:

Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk

Menaka C. Thounaojam, Duafalia F. Dudimah, Samuel T. Pellom Jr., Roman V. Uzhachenko, David P. Carbone, Mikhail M. Dikov and Anil Shanker _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:32439-32455. https://doi.org/10.18632/oncotarget.5857

Metrics: PDF 1600 views  |   HTML 1967 views  |   ?  


Abstract

Menaka C. Thounaojam1,*, Duafalia F. Dudimah1,*, Samuel T. Pellom Jr. 1,2,3, Roman V. Uzhachenko1, David P. Carbone4, Mikhail M. Dikov4 and Anil Shanker1,3,5

1 Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN, USA

2 Department of Microbiology and Immunology, School of Medicine, Meharry Medical College, Nashville, TN, USA

3 School of Graduate Studies and Research, Meharry Medical College, Nashville, TN, USA

4 Department of Medicine, James Cancer Center, The Ohio State University, Columbus, OH, USA

5 Host-Tumor Interactions Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

* These authors have contributed equally as first co-authors

Correspondence to:

Anil Shanker, email:

Keywords: Notch signaling, NF-κB, cancer immunosuppression, T cell Immunotherapy, proteasome inhibition, Immunology and Microbiology Section, Immune response, Immunity

Received: August 13, 2015 Accepted: September 09, 2015 Published: September 28, 2015

Abstract

The immunosuppressive tumor microenvironment usurps host antitumor immunity by multiple mechanisms including interference with the Notch system, which is important for various metazoan cell fate decisions and hematopoietic cell differentiation and function. We observed that treatment with the proteasome inhibitor bortezomib in mice bearing various solid tumors resulted in an upregulated expression of various Notch signaling components in lymphoid tissues, thereby increasing CD8+T-lymphocyte IFNγ secretion and expression of effector molecules, perforin and granzyme B, as well as the T-box transcription factor eomesodermin. Bortezomib also neutralized TGFβ-mediated suppression of IFNγ and granzyme B expression in activated CD8+T-cells. Of note, bortezomib reversed tumor-induced downregulation of Notch receptors, Notch1 and Notch2, as well as increased the levels of cleaved Notch intracellular domain (NICD) and downstream targets Hes1 and Hey1 in tumor-draining CD8+T-cells. Moreover, bortezomib promoted CD8+T-cell nuclear factor-κB (NFκB) activity by increasing the total and phosphorylated levels of the IκB kinase and IκBα as well as the cytoplasmic and nuclear levels of phosphorylated p65. Even when we blocked NFκB activity by Bay-11-7082, or NICD cleavage by γ-secretase inhibitor, bortezomib significantly increased expression of Notch Hes1 and Hey1 genes as well as perforin, granzyme B and eomesodermin in activated CD8+T-cells. Data suggest that bortezomib can rescue tumor-induced dysfunction of CD8+T-cells by its intrinsic stimulatory effects promoting NICD-NFκB crosstalk. These findings provide novel insights on using bortezomib not only as an agent to sensitize tumors to cell death but also to provide lymphocyte-stimulatory effects, thereby overcoming immunosuppressive actions of tumor on anti-tumor T-cell functions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5857